At the onset of tumors, positive immune regulatory cells, such as CD8+T cells, have predicted good prognosis in NSCLC patients [21], while negative immune regulatory cells, such as Tregs and tumor-associated macrophages (TAMs), may accelerate tumor progression [22, 23]. The gene discussed is CD8A; the disease is neoplasm.